Compositions and methods for treating phenylketonuria
US-2024141381-A1 · May 2, 2024 · US
Isolated bacteriophage having E. coli-specific bactericidal activity and antibacterial composition comprising the same
US9358258B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9358258-B2 |
| Application number | US-201214345189-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2012 |
| Priority date | Nov 14, 2011 |
| Publication date | Jun 7, 2016 |
| Grant date | Jun 7, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a novel bacteriophage having an E. coli -specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli , and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E. coli , and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for restraining or retarding progress of, or treating, an infectious disease caused by Enterotoxigenic Eschericial coli , comprising the step of administering a bacteriophage identified by Accession No. KCCM11217P to a mammal in need of treatment. 2. The method according to claim 1 , wherein the mammal is a pig. 3. A method for restraining or retarding progress of, or treating, an infectious disease caused by Enterotoxigenic Escherichia coli , comprising the step of administering a composition comprising a bacteriophase identified by Accession No. KCCM11217P as an active ingredient to a mammal in need of treatment. 4. The method according to claim 3 , wherein the infectious disease caused by Enterotoxigenic Escherichia coli is colibacillosis. 5. The method according to claim 3 , wherein the mammal is a pig.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title
- A61K35/76Primary
Viruses; Subviral particles; Bacteriophages · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9358258B2 cover?
- The present invention relates to a novel bacteriophage having an E. coli -specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an …
- Who is the assignee on this patent?
- Cj Cheiljedang Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K35/76. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).